Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants

Phase 1 Completed 18 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate pharmacokinetics (explores what the body does to the drug), safety and tolerability of single and multiple-dose of tapentadol in healthy participants.

Timeline

Start: 2008-09
Primary completion: 2008-10
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tapentadol	Small molecule	250 mg	Oral

Indications

No indication recorded.